Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Authors
- Carl J. Danzig (ORCID: https://orcid.org/0000-0002-7422-802X)
- Masahiko Shimura (ORCID: https://orcid.org/0000-0001-5456-6374)
- Jeffrey R. Willis (ORCID: https://orcid.org/0000-0002-6712-1144)
- Lars‐Olof Hattenbach (ORCID: https://orcid.org/0000-0002-5275-8118)
- Timothy Y. Y. Lai (ORCID: https://orcid.org/0000-0002-7832-6428)
- Francis Abreu (ORCID: https://orcid.org/0000-0001-8762-3128)
- Faruque Ghanchi (ORCID: https://orcid.org/0000-0002-4448-8162)
- Anne-Cecile Retiere
- Arshad M. Khanani (ORCID: https://orcid.org/0000-0001-8928-5599)
- Liliana P Paris (ORCID: https://orcid.org/0000-0002-9312-9924)
- Pablo Arrisi
- Patricio G. Schlottmann (ORCID: https://orcid.org/0000-0003-0196-0452)
- Christiana Dinah (ORCID: https://orcid.org/0000-0002-0815-4771)
- Ying Liu (ORCID: https://orcid.org/0000-0001-7035-5542)
Institutions
- Imperial College Healthcare NHS Trust (GB)
- Chinese University of Hong Kong (HK)
- London North West Healthcare NHS Trust (GB)
- Tokyo Medical University Hachioji Medical Center (JP)
- Roche (United Kingdom) (GB)
- Klinikum Ludwigshafen (DE)
- Sierra Eye Associates (US)
- Bradford Teaching Hospitals NHS Foundation Trust (GB)
- Florida Atlantic University (US)
Publication Details
- Journal
- Ophthalmology Retina
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1016/j.oret.2025.03.005
- Citations
- 11
- Primary Topic
- Retinal and Optic Conditions
- Type
- article
- Field-Weighted Citation Impact
- 18.78
Funders
- F. Hoffmann-La Roche